Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 20/20 | 0.59 |
| ▸ | GABRG2 | P18507 | 20/20 | 0.59 |
| ▸ | GABRB3 | P28472 | 20/20 | 0.59 |
| ▸ | GABRA3 | P34903 | 20/20 | 0.59 |
| ▸ | GABRA5 | P31644 | 18/20 | 0.59 |
| ▸ | GABRA2 | P47869 | 17/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885796 | 0.88 | GABRG2 (0.59) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2883297 | 0.71 | HRH3 (0.61) | — | |
| SCHEMBL10666232 | 0.68 | GABRG2 (0.74) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2652789 | 0.68 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL22027531 | 0.67 | GABRA1 (0.53) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2886577 | 0.66 | HRH3 (0.54) | — | |
| SCHEMBL13262200 | 0.66 | CYP1A2 (0.83) | — | |
| SCHEMBL4760902 | 0.66 | CACNA2D1 (1.00) | GABRA1GABRG2GABRB3GABRA3GABRA5 | |
| SCHEMBL2879899 | 0.66 | HRH3 (0.59) | — | |
| SCHEMBL2646920 | 0.64 | GABRA1 (0.81) | GABRA1GABRG2GABRB3GABRA3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645756-B2 | 6-[4-(3-piperidin-1-ylpropoxy)-phenyl]-[1,2,4]triazolo[4,3-b]pyridazine; has histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect; for metabolic system, circulatory system or nervous system diseases | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | MSD K.K. (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1719756-A1 | NITROGENOUS FUSED HETEROAROMATIC RING DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167453-A1 | Nitrogenous fused heteroaromatic ring derivative | HRH3, HRH2, HRH4 | GABRA1 517/4885GABRG2 1143/4885GABRB3 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.